• Email:sales@AmericanPharmaWholesale.com
  • Site Map




Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


Menu

RX ITEM-KANJINTI 150 MG SDV Vial By Genentech Healthcare

KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258  NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101  UPC/GTIN No. 3-55513-14101-7 355513-141017KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solutionOnly Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Herceptin 150Mg Powder Vial By GenentechHerceptin 150Mg Powder Vial By GenentechKANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258  NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101  UPC/GTIN No. 3-55513-14101-7 355513-141017KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution

RX ITEM-KANJINTI 150 MG SDV Vial By Genentech Healthcare

$1584.54$1349.00

KANJINTI 150 MG SDV trastuzumab-anns INTRAVEN VIAL 150 MG Vial By Genentech Healthcare Item No.:RX932158 931258 NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101 UPC/GTIN No. 3-55513-14101-7 355513-141017 355513141017 MPN 14101 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX item. Rx Item No. Rx276701

Have a question?

These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI.

KANJINTI™ (trastuzumab-anns) for injection, for intravenous use
Initial U.S. Approval: 2019

KANJINTI (trastuzumab-anns) is biosimilar* to HERCEPTIN® (trastuzumab)
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY
See full prescribing information for complete boxed warning

Cardiomyopathy: Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue KANJINTI for cardiomyopathy. (2.3, 5.1)

Infusion Reactions, Pulmonary Toxicity: Discontinue KANJINTI for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. (5.2, 5.4)

Embryo-Fetal Toxicity: Exposure to trastuzumab products during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of these risks and the need for effective contraception. (5.3, 8.1, 8.3)
RECENT MAJOR CHANGES
Dosage and Administration (2.4) 10/2019
INDICATIONS AND USAGE

KANJINTI is a HER2/neu receptor antagonist indicated for:

the treatment of HER2 overexpressing breast cancer. (1.1, 1.2)
the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (1.3)

Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product (1, 2.1).
DOSAGE AND ADMINISTRATION

For intravenous (IV) infusion only. Do not administer as an IV push or bolus. (2.2)

Do not substitute KANJINTI (trastuzumab-anns) for or with ado-trastuzumab emtansine. (2.2)

Perform HER2 testing using FDA-approved tests by laboratories with demonstrated proficiency. (1, 2.1)

Adjuvant Treatment of HER2-Overexpressing Breast Cancer (2.2)

Administer at either:

Initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin). One week after the last weekly dose of KANJINTI, administer 6 mg/kg as an IV infusion over 30�'90 minutes every three weeks to complete a total of 52 weeks of therapy, or
Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30�"90 minutes IV infusion every three weeks for 52 weeks.

Metastatic HER2-Overexpressing Breast Cancer (2.2)

Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions.

Metastatic HER2-Overexpressing Gastric Cancer (2.2)

Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks.

DOSAGE FORMS AND STRENGTHS

For Injection: 150 mg lyophilized powder in a single-dose vial for reconstitution
For Injection: 420 mg lyophilized powder in a multiple-dose vial for reconstitution

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

Exacerbation of Chemotherapy-Induced Neutropenia. (5.5, 6.1)

ADVERSE REACTIONS

Adjuvant Breast Cancer

Most common adverse reactions (≥ 5%) are headache, diarrhea, nausea, and chills. (6.1)

Metastatic Breast Cancer

Most common adverse reactions (≥ 10%) are fever, chills, headache, infection, congestive heart failure, insomnia, cough, and rash. (6.1)

Metastatic Gastric Cancer

Most common adverse reactions (≥ 10%) are neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia. (6.1)



To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS

Females and Males of Reproductive Potential: Verify the pregnancy status of females prior to initiation of KANJINTI (8.3).

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of KANJINTI has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 10/2019

KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258  NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101  UPC/GTIN No. 3-55513-14101-7 355513-141017
KANJINTI- trastuzumab-anns inj
KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258 NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101 UPC/GTIN No. 3-55513-14101-7 355513-141017

KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution
KANJINTI- trastuzumab-anns inj
KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
TRASTUZUMAB INTRAVEN VIAL
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Herceptin 150Mg Powder Vial By Genentech
Herceptin 150Mg Powder Vial By
Herceptin 150Mg Powder Vial By Genentech

Herceptin 150Mg Powder Vial By Genentech
Herceptin 150Mg Powder Vial By
Herceptin 150Mg Powder Vial By Genentech

KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258  NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101  UPC/GTIN No. 3-55513-14101-7 355513-141017
KANJINTI- trastuzumab-anns inj
KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution Item No.:RX932158 931258 NDC No.55513-0141-01 55513-141-01 55513-141-01 55513014101 UPC/GTIN No. 3-55513-14101-7 355513-141017

KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution
KANJINTI- trastuzumab-anns inj
KANJINTI- trastuzumab-anns injection, powder, lyophilized, for solution